Últimas noticias sobre PTL (NASDAQ:PTLE) Bolsa

PTL Ltd is a holding company. Through its subsidiaries, it is an established bunkering facilitator providing marine fuel logistics services for vessel refuelling, primarily serving the Asia Pacific market. As a bunker facilitator, the Group's services mainly involve facilitating with its suppliers to supply fuel for the use by the customers' vessels at various ports along their voyages in the Asia Pacific region; arranging vessel refuelling activities at competitive pricing to the customers; offering trade credit to the customers for vessel refuelling; handling unforeseeable circumstances faced by the customers and providing contingency solutions to the customers in a timely manner; and handling disputes, mainly in relation to quality and quantity issues on marine fuel, if any.

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

MIND

PTLE

PTL Ltd y Mind Technology muestran RSI sobrecomprado, lo que podría ser una señal de alerta para inversores.

2 acciones energéticas con RSI en sobrecompra: ¿Advertencia para los inversores?

PTL Ltd

Scotiabank analyst Patrick Colville maintains SolarWinds (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>) with a Sector Perform and raises the price target from $15 to $18.5.

Price Target

Analyst Ratings

Scotiabank Maintains Sector Perform on SolarWinds, Raises Price Target to $18.5

<a href="https://x.com/AFP/status/1888955702896431214" title="https://x.com/AFP/status/1888955702896431214">https://x.com/AFP/status/1888955702896431214</a>

Politics

General

iShares MSCI Israel Capped Investable Market Index Fund

President Trump Says 'No Right Of Return' For Palestinians Under Gaza Takeover Plan

WIIM

BOOM

DMC Global shares are trading higher after the company announced a non-binding acquisition proposal from Steel Connect

The rise of artificial intelligence (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ai#NYSE">AI</a>) and cloud computing has revolutionized business operations while also increasing cybersecurity risks. As threats become more advanced, AI-driven security solutions are now crucial for safeguarding sensitive data, preventing breaches and detecting fraud in real-time.
This shift has positioned AI-powered cybersecurity as a key long-term investment theme, driving growth opportunities for leading companies like CrowdStrike CRWD &amp; Cloudflare Inc NET.
<h2>What is Cloud AI?</h2>
Cloud AI refers to AI tools and services that run on cloud computing platforms like Google Cloud, which is part of Google&#39;s parent company, Alphabet Inc. GOOGL; Amazon Web Services (AWS), a division of Amazon AMZN; and Microsoft Azure, a division of Microsoft MSFT. Instead of installing software on a personal computer or a company&#39;s servers, businesses can use AI-powered tools hosted in the cloud to analyze massive amounts of data, detect anomalies and make security decisions.
<h2>How AI is Revolutionizing Cybersecurity</h2>
Traditional cybersecurity tools rely on rules and signatures to detect threats, which means they need to be updated regularly to recognize new attacks. However, cybercriminals are constantly finding new ways to break into systems. AI-powered cybersecurity, on the other hand, learns and adapts to new threats without human intervention.
To highlight some of the key benefits, AI-powered cybersecurity enables real-time threat detection, instantly identifying suspicious activities within networks to prevent data breaches before they occur. AI can also take immediate action through automated incident response, such as blocking malicious connections or isolating compromised systems without human intervention. Additionally, AI plays a crucial role in fraud prevention, detecting fraudulent activities in banking, e-commerce and online transactions with high accuracy. One of its most significant advantages is zero-day attack defense, where AI identifies and mitigates never-before-seen cyber threats, ensuring proactive security against evolving cyber risks.
<h2>Bet on Two AI Cybersecurity Leaders: CRWD &amp; NET</h2>
Considering the backdrop, investors should include these two AI Cybersecurity stocks in their portfolios.
CrowdStrike
CrowdStrike&#39;s AI-native cybersecurity platform enables businesses and governments to proactively detect and stop cyber threats before they escalate. Its cloud-based Falcon platform integrates AI-driven threat intelligence, identity protection and next-gen SIEM, driving rapid enterprise adoption. With increasing consolidation of security tools and growing demand for AI-powered protection, CrowdStrike is positioned as a leader in modern cybersecurity transformation. The stock currently carries a Zacks Rank #2 (Buy). You can see&nbsp;<a href="https://www.zacks.com/stocks/buy-list/?ADID=zp_1link_invideas&amp;ICID=zpi_1link_invideas">the complete list of today&#39;s Zacks #1 Rank (Strong Buy) stocks here</a>.
Cloudflare
Cloudflare leverages AI-driven security to protect global enterprises, including government agencies, from evolving cyber threats. Its platform mitigates DDoS attacks, enhances Zero Trust architecture and delivers high-performance AI-powered security. With a scalable, efficient network and increasing enterprise adoption, #2 Ranked Cloudflare is positioned for long-term growth as cybersecurity, AI and digital modernization remain top enterprise priorities.
&nbsp;
<h2>Just Released: Zacks Top 10 Stocks for 2025</h2>
Hurry &ndash; you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&amp;P 500&#39;s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential. 
&nbsp;
<a href="https://www.zacks.com/registration/top10/welcome/eoffer/5283?adid=SYND_BENZ_ZU_TOP10POST_ANALYSTBLOG_215_IND_02102025_2412571&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2412571" style="font-weight:bold">See New Top 10 Stocks &gt;&gt;</a>
&nbsp;
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href="https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&amp;ADID=SYND_BENZ_7BEST_ANALYSTBLOG_215_2412571&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2412571" target="_blank">Click to get this free report</a>

&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=AMZN&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_215_2412571_AMZN&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2412571">Amazon.com, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=MSFT&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_215_2412571_MSFT&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2412571">Microsoft Corporation (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=GOOGL&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_215_2412571_GOOGL&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2412571">Alphabet Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/googl#NASDAQ">GOOGL</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=CRWD&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_215_2412571_CRWD&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2412571">CrowdStrike (CRWD): Free Stock Analysis Report</a> 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=NET&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_215_2412571_NET&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2412571">Cloudflare, Inc. (NET): Free Stock Analysis Report</a>
<a href="https://www.zacks.com/stock/news/2412571/cyber-threats-escalating-globally-time-to-bet-on-crwd-net?cid=CS-BENZ-FT-analyst_blog|investment_ideas-2412571">To read this article on Zacks.com click here.</a>
<a href="https://www.zacks.com/">Zacks Investment Research</a>

Equities

Tech

AMZN

GOOGL

MSFT

Cyber Threats Escalating Globally: Time to Bet on CRWD & NET?

On Saturday, 4D Molecular Therapeutics&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) announced initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM trial of 4D-150 in a broad wet age-related macular degeneration (wet AMD) patient population.
Additional data were provided on the durability of aflibercept expression <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43579183/4dmt-presents-positive-52-week-results-from-phase-2b-cohort-of-prism-wet-amd-study-and-long-term-d" rel="noreferrer noopener">for up to two years</a>.
Topline 52-Week Efficacy Results for 4D-150 3E10 vg/eye (Planned Phase 3 Dose) from Phase 2b Population Extension Cohort of PRISM (Data Cut-Off January 15, 2025):
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40945849/4d-molecular-therapeutics-stock-falls-after-follow-up-data-from-mid-stage-study-of-vision-loss-dr" rel="noreferrer noopener">4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate</a>
In a subgroup of 30 patients who received supplemental injections of Regeneron Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Eylea (aflibercept), an 83% reduction in injection burden was observed. This represents 0.97 mean supplemental injections per patient over 52-weeks vs. 6.0 injections projected with on-label aflibercept 2 mg Q8W.
<ul>
<li>70% required 0-1 supplemental injection, and 57% were injection-free through 52 weeks.</li>
<li>Improved and maintained best corrected visual acuity (BCVA) of +2.2 letters.</li>
<li>Durable central subfield thickness (CST) improved with fewer fluctuations, as measured by optical coherence tomography (OCT), of -11 µm; -13 µm in supplemental injection-free patients.</li>
</ul>
In the recently diagnosed subgroup, 87% required 0-1 supplemental injection, and 80% were injection-free through 52 weeks.
<ul>
<li>A 94% reduction in injection burden was observed over 52 weeks vs. 6.0 injections projected with on-label aflibercept 2 mg Q8W</li>
<li>Improved and maintained BCVA of +3.1 letters</li>
<li>Durable CST improvement with fewer fluctuations, as measured by OCT, of -10 µm; -20 µm in supplemental injection-free patients</li>
</ul>
4D-150 continues to be well tolerated during up to three years of follow-up in all patients treated with 3E10 vg/eye
No 4D-150–-related hypotony, endophthalmitis, vasculitis, occlusive/non-occlusive retinal vasculitis, or choroidal effusions have been observed to date
4D-150 Program Milestones
<ul>
<li>4FRONT-1 and 4FRONT-2 Phase 3 trials are expected to initiate in Q1 and Q3 2025, respectively.</li>
<li>Two-year Phase 1/2a and 18-month Phase 2b PRISM data are expected in Q4 2025.</li>
<li>Primary endpoint 52-week topline data from both 4FRONT-1 and 4FRONT-2 expected in H2 2027.</li>
</ul>
Price Action: FDMT stock is down 8.54% at $5.46 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/02/43593007/rivian-commercial-van-now-available-for-fleets-nationwide-in-us" target="_blank" rel="noreferrer noopener">Rivian Commercial Van Now Available For Fleets Nationwide In US</a></li>
</ul>

Biotech

Health Care

Movers

FDMT

REGN

Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study

Strategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) has expanded its Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) holdings with a <a href="https://www.benzinga.com/insights/options/25/02/43594268/microstrategys-options-frenzy-what-you-need-to-know">significant new purchase</a>, acquiring 7,633 BTC for approximately $742.4 million at an average price of $97,255 per Bitcoin.
What Happened: The <a href="https://www.strategy.com/press/strategy-acquires-7633-btc-and-now-holds-478740-btc_02-10-2025">acquisition</a>, made between Feb. 3 and Feb. 9, was funded through proceeds from stock sales under its $21 billion equity offering program and its recently completed $563.4 million preferred stock offering.
With this latest purchase, Strategy now holds a total of 478,740 BTC, acquired at an average cost of $65,033 per Bitcoin.
Michael Saylor, Strategy's co-founder and executive chairman, has remained vocal about the company's long-term commitment to Bitcoin, often describing it as the best store of value in the digital age. 
The latest acquisition further cements Strategy&#8217;s position as the largest corporate holder of Bitcoin, aligning with its strategy of using public and private funding to accumulate the cryptocurrency.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43591727/coinbase-ceo-brian-armstrong-says-bitcoin-adoption-to-reach-billions-by-2030">Coinbase CEO Brian Armstrong Says Bitcoin Adoption To Reach &#8216;Billions&#8217; By 2030</a>
Why It Matters: The company has consistently leveraged equity sales and debt offerings to fund its purchases, a strategy that has significantly influenced its stock price movements.
The firm has $4.17 billion in shares still available for sale, indicating that additional Bitcoin purchases may be forthcoming. 
Strategy Inc.&#8217;s bold Bitcoin accumulation strategy has received mixed reactions from analysts. 
Mizuho recently began covering the stock with an ‘outperform' rating and set a price target of $515, describing the company as a &#8220;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43333849/microstrategy-is-a-lever-for-the-believer-says-mizuho-initiates-coverage-on-bitcoins-levered-play-with-an-outperform-rating#:~:text=MSTR%20has%20a%20consensus%20'buy,%2C%20implying%20a%2075.57%25%20upside.">Lever for the Believer</a>&#8221; in Bitcoin, emphasizing its appeal to investors who view Bitcoin as a long-term asset.
Despite this optimism, questions persist regarding the sustainability of Strategy&#8217;s valuation, particularly in relation to the value of its Bitcoin holdings. 
Some market observers have raised concerns about whether the <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43545769/microstrategy-rebrands-as-strategy-unveils-new-logo-and-bitcoin-focused-identity">company's stock price accurately reflects its assets</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43590115/trump-meme-coin-left-a-sour-taste-in-traders-mouths-10x-research">TRUMP Meme Coin Left A Sour Taste In Traders&#8217; Mouths: 10x Research</a></li>
</ul>
Image: Shutterstocl

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

Strategy Acquires 7,633 Bitcoin For $742.4 Million, Boosts Holdings To 478,740 BTC

JMP Securities analyst Nicholas Jones reiterates Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) with a Market Outperform and maintains $42 price target.

Reiteration

XMTR

JMP Securities Reiterates Market Outperform on Xometry, Maintains $42 Price Target

Corporate America is cheering the strongest earnings season in three years, with S&amp;P 500 companies posting a 16.4% year-over-year earnings growth rate in fourth quarter of 2024—the <a href="https://www.benzinga.com/markets">best since late 2021. </a>
Yet, despite the robust numbers, investor optimism is tempered by renewed trade uncertainty. 
President Donald Trump's tariff plans have become a dominant theme on earnings calls, raising concerns about rising costs and supply chain disruptions.
<h3 class="wp-block-heading">Earnings Surge: S&amp;P 500 Posts Strongest Growth Since 2021</h3>
The S&amp;P 500's blended earnings growth rate for fourth quarter 2024 stands at 16.4%, according to FactSet&#8216;s latest data, significantly outpacing initial forecasts. If this number holds, it will mark the strongest annual earnings growth since the fourth quarter of 2021.
So far, 62% of S&amp;P 500 companies have reported earnings, with 77% surpassing earnings-per-share estimates and 63% exceeding revenue forecasts. The average earnings surprise stands at 7.5%, comfortably above the 10-year average of 6.7%.
The average earnings surprise was 7.5%, below the 5-year average of 8.5% but above the 10-year one of 6.7%.
FactSet highlighted that the earnings outlook has improved as more companies report results. 
&#8220;On Dec. 31, the estimated (year-over-year) earnings growth rate for the S&amp;P 500 for Q4 2024 was 11.8%. Eight sectors are reporting higher earnings today (compared to December 31) due to positive EPS surprises,&#8221; FactSet wrote. 
Among the standout sectors and companies:
<ul>
<li>Financials: Earnings soared 51.2%, led by strong bank results from Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) and JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>).</li>
<li>Consumer Discretionary: Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) fueled 24.6% sector growth after reporting EPS of $1.86, well above the $1.49 estimate.</li>
<li>Communication Services: Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) led 30.2% growth, posting EPS of $8.02, smashing expectations of $6.76.</li>
</ul>
<h2 class="wp-block-heading">Tariff Fears Surge as Key Business Concern</h2>
While earnings have surprised to the upside, 146 S&amp;P 500 companies have mentioned "tariffs" during their earnings calls—the highest number since mid-2019, according to FactSet. 
If the current trend continues, the fourth quarter of 2024 could set a 10-year record for the number of companies discussing tariff-related concerns.
Industrials have been at the center of the discussion, with 39 companies citing tariff risks. The materials and utilities sectors have also been hit hard, with more than 80% of companies in these industries addressing the issue.
With Trump imposing a <a href="https://www.benzinga.com/government/regulations/25/02/43592144/us-steel-aluminum-stocks-rally-as-trump-revives-25-tariff-plan">25% tariff on steel and aluminum imports</a> and hinting at reciprocal tariffs on all countries, businesses are struggling to gauge the potential impact. 
Some executives have warned of higher costs, supply chain disruptions, and margin pressure, but many remain uncertain about the ultimate financial toll.
Among the S&amp;P 500 firms providing forward guidance, 30 have chosen to exclude tariff effects altogether due to the unpredictable nature of trade policy, while 21 have incorporated tariff risks into their outlooks but widened their forecast ranges to account for potential volatility.
Also Read: <a href="https://www.benzinga.com/25/02/43592025/fast-food-major-mcdonalds-stocks-rise-despite-q4-sales-miss-details">McDonald&#8217;s Q4 Earnings: Stagnant Revenue Growth, US Comp Sales Decline And More</a>
<h3 class="wp-block-heading">Muted Market Reaction Despite Strong Earnings</h3>
Despite the stellar earnings reports, stock price reactions have been subdued. Companies that beat EPS estimates have seen their stock prices rise by just 0.3% on average, well below the five-year average of 1.0%. 
Meanwhile, stocks missing estimates have dropped 2.4%, slightly worse than the five-year average decline of 2.3%.
&#8220;To date, the market is rewarding positive earnings surprises reported by S&amp;P 500 companies for Q4 less than average and punishing negative earnings surprises reported by S&amp;P 500 companies for Q4 slightly more than average,&#8221; FactSet wrote.
The uncertainty surrounding tariffs may be playing a role in this muted reaction. 
Investors, while encouraged by strong earnings, appear hesitant to fully price in optimism amid concerns over potential disruptions to supply chains and rising input costs.
<h3 class="wp-block-heading">Looking Ahead: Will Tariffs Derail Growth?</h3>
Wall Street analysts currently expect S&amp;P 500 earnings to grow 8.7% in the first quarter of 2025 and 10.2% in the second quarter. Yet, those forecasts could come under pressure if tariffs begin to weigh on corporate margins and consumer demand.
For now, corporate America is delivering some of the strongest earnings growth in years, but the real test may come in the months ahead as trade tensions escalate.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43564020/consumer-sentiment-sinks-economist-flags-unusually-large-rise-in-inflation-perception">Consumer Sentiment Sinks In February: Economist Flags &#8216;Unusually Large&#8217; Rise In Inflation Perception</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Government

Large Cap

Macro Economic Events

Regulations

Econ #s

Economics

Corporate America's Best Earnings In 3 Years: Will Tariffs End Wall Street's Honeymoon?

Scotiabank analyst Ben Isaacson maintains Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) with a Sector Outperform and raises the price target from $59 to $60.

Scotiabank Maintains Sector Outperform on Nutrien, Raises Price Target to $60

Market Summary

CENX

Benzinga Market Summary: Trump Reportedly Plans Tariffs On Steel And Aluminum Imports, Gold Rises On Uncertainty, SSJ Reports Elliott Has Taken Stake In BP

MBOT

Microbot Medical shares are trading lower after the company announced a $13 million registered direct offering.

Rockwell Automation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) shares surged after the company reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43588368/rockwell-automation-reports-first-quarter-2025-results" rel="noreferrer noopener">better-than-expected first-quarter results.</a>
Sales fell 8.4% year over year and slid 7.6% organically to $1.881 billion, in line with the consensus of $1.881 billion.
Segment Details: Intelligent Devices sales declined 13.1% to $806 million, Software &amp; Control fell 12.4% to $529 million, and Lifecycle Services rose 5% to $546 million.
Total ARR grew 11%. Adjusted EPS was $1.83 (-10% YoY), <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">above the analyst consensus of $1.59.</a>
Total segment operating earnings for the quarter fell 10% year-over-year to $321 million. Segment operating margin declined slightly to 17.1% from 17.3%, impacted by lower sales volume, though partially offset by cost reductions and margin expansion efforts.
Operating cash flow was $364 million, up from $33 million year over year. Free cash flow reached $293 million, compared to a $35 million outflow last year. The increase was mainly due to no payout of incentive compensation in the&nbsp;first quarter&nbsp;of fiscal 2025 related to fiscal 2024 performance.
&#8220;From a demand perspective, we are encouraged by better-than-expected order performance in the quarter with sequential growth across all regions and business segments. While there is still some macroeconomic and policy uncertainty weighing on customers' capex plans, Rockwell won multi-million dollar strategic orders across key industries, especially in the U.S., our home market,&#8221; commented Blake Moret, Chairman and CEO.
&#8220;Q1 margins and EPS came in well above our expectations this quarter, reflecting some early benefits of Rockwell&#8217;s renewed focus on operational excellence and cost discipline,&#8221; added Moret.
The company repurchased 0.4 million shares for $99 million during the quarter. As of December 31, $1.2 billion remained under existing repurchase authorizations.
Return on Invested Capital for the twelve months ended December 31, 2024, was 14.5%, down from 18.5% in the prior year, primarily due to lower pre-tax net income.
FY25 Outlook updates: Rockwell continues to expect adjusted EPS of $8.60 – $9.80 versus the $9.40 estimate.
The company lowered sales midpoint expectations to ~$8.1 billion from the prior view of ~$8.2 billion <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">versus the $8.225 billion estimate.</a>
The company updated fiscal 2025 reported sales growth range to (5.5)% &#8211; 0.5% due to ~(1.5)% FX impact to sales, reaffirmed organic sales growth range of (4)% &#8211; 2%.
Price Action: ROK shares are trading higher by 9.36% at $293.51 at the last check Monday.
Photo via Shutterstock.

Earnings

Guidance

Rockwell Automation Defies Q1 Sales Decline With Cost Discipline And Strong Cash Flow; Stock Jumps

Monday.com Ltd&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) reported fiscal fourth-quarter 2024 revenue growth of 32% year-on-year to $267.98 million, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43588350/monday-com-announces-fourth-quarter-and-fiscal-year-2024-results" rel="noreferrer noopener">analyst consensus estimate of $261.37 million</a>.&nbsp;
The project management software&nbsp;company&#8217;s&nbsp;adjusted EPS of $1.08 beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $0.79</a>. The&nbsp;stock price climbed after the results.
Also Read: <a href="https://www.benzinga.com/25/02/43561852/cboe-q4-earnings-growth-driven-by-strong-options-trading-and-global-equities-ceo-highlights-market-expansion" target="_blank" rel="noreferrer noopener">Cboe Q4 Earnings: Options Boom, Global Growth, Market Expansion Drive Gains</a>
The net dollar retention rate was 112%&nbsp;and 115%&nbsp;for customers with more than ten users.
The number of paid customers with over $50,000 in annual recurring revenue (ARR) rose 39%&nbsp;year over year&nbsp;to 3,201. The adjusted operating margin increased 500 bps to 15%.
In the quarter, Monday.com generated:
<ul>
<li>Operating cash flow of $76.7 million</li>
<li>$72.7 million of free cash flow, compared to $58.5 million and $55.4 million, respectively, a year ago.</li>
<li>$1.46 billion in cash and equivalents as of Dec. 31, 2024.</li>
</ul>
Roy Mann and Eran Zinman, co-founders and co-CEOs, flagged the expansion of its product suite with Monday service, which is already seeing rapid adoption from both existing and new customers.
They also highlighted that the company doubled down on its AI efforts, focusing on AI Blocks, Product Power-ups, and a new Digital Workforce of AI Agents for 2025. They expect AI to be a game-changer for their customers, giving them the ability to transform their workflows and scale faster than ever before.
Outlook:&nbsp;Monday.com expects fiscal first-quarter 2025 revenue of $274 million—$274.32&nbsp;million (versus the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">consensus of $246.1 million</a>) and an adjusted operating margin of 9%–10%.
Monday.com expects 2025 revenue of $1.208 billion—$1.221 billion, against the consensus of $1.210 billion, and an adjusted operating margin of 11%–12%.
Monday.com stock surged over 57% in the last 12 months. At least four Wall Street firms reduced their price target on the stock in 2025. However, Citigroup <a target="_blank" href="https://www.benzinga.com/quote/MNDY/analyst-ratings" rel="noreferrer noopener">upgraded its rating</a> from Neutral to Buy, and Cantor Fitzgerald initiated coverage on the stock with an Overweight.
Price Action: Monday.com stock is up 30.4% at $334.76 at the last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/02/43535385/thomson-reuters-q4-earnings-beats-estimates-boosts-dividend-10-ceo-highlights-strategic-growth" target="_blank" rel="noreferrer noopener">Thomson Reuters Q4 Earnings: Beats Estimates, Boosts Dividend 10%, CEO Highlights Strategic Growth</a></li>
</ul>
Image: Shutterstock

MNDY

Monday.com Beats Q4 Earnings Estimates, Boasts 32% Revenue Growth: CEO Calls AI A Game-Changer

JMP Securities analyst Mitch Germain reiterates Terreno Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>) with a Market Outperform and maintains $72 price target.

TRNO

JMP Securities Reiterates Market Outperform on Terreno Realty, Maintains $72 Price Target

Scotiabank analyst Divya Goyal maintains Converge Tech Solns (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CTS#TSX">CTS</a>) with a Sector Perform and raises the price target from C$4 to C$5.5.

TSX:CTS

Scotiabank Maintains Sector Perform on Converge Tech Solns, Raises Price Target to C$5.5

Amkor Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) will release its fourth-quarter financial results after the <a href="https://www.benzinga.com/quote/AMKR/earnings">closing bell on Monday, Feb. 10.</a>
Analysts expect the Tempe, Arizona-based company to report quarterly earnings at 38 cents per share, down from 48 cents per share in the year-ago period. Amkor projects quarterly revenue of $1.66 billion, compared to $1.75 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Dec. 16, 2024, Amkor Technology named John Liu to Board of Directors.
Amkor shares fell 1.1% to close at $24.33 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/WBA/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>DA Davidson analyst Thomas Diffely maintained a Buy rating and cut the price target from $40 to $36 on Oct. 29, 2024. This analyst has an accuracy rate of 69%.</li>
<li>Goldman Sachs analyst Toshiya Hari maintained a Neutral rating and cut the price target from $36 to $32 on Oct. 29, 2024. This analyst has an accuracy rate of 81%.</li>
<li>Keybanc analyst Steve Barger maintained an Overweight rating and lowered the price target from $38 to $34 on Oct. 29, 2024. This analyst has an accuracy rate of 73%.</li>
<li>Morgan Stanley analyst Joseph Moore maintained an Equal-Weight rating and cut the price target from $35 to $26 on Oct. 29, 2024. This analyst has an accuracy rate of 71%.</li>
<li>Needham analyst Charles Shi maintained a Buy rating and lowered the price target from $45 to $34 on Oct. 29, 2024. This analyst has an accuracy rate of 63%.</li>
</ul>
Considering buying AMKR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="484" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10051127/image-74-1024x484.png" alt="" class="wp-image-774174" style="width:591px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10051127/image-74-1024x484.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10051127/image-74-300x142.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10051127/image-74-768x363.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10051127/image-74.png 1118w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43559194/jim-cramer-likes-this-utilities-stock-i-think-youve-got-a-good-one">Jim Cramer Likes This Utilities Stock: &#8216;I Think You&#8217;ve Got A Good One&#8217;</a></li>
</ul>

AMKR

Amkor Technology Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

GSAT

Globalstar shares are trading higher after MDA Space signed a definitive contract with the company to be the prime contractor for the satellite operator's next generation low Earth orbit constellation.

U.S. stocks traded higher this morning, with the Dow Jones index gaining around 100 points on Monday.
Following the market opening Monday, the Dow traded up 0.24% to 44,407.91 while the NASDAQ gained 0.89% to 19,696.41. The S&amp;P 500 also rose, gaining, 0.43% to 6,051.88.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43559194/jim-cramer-likes-this-utilities-stock-i-think-youve-got-a-good-one">Jim Cramer Likes This Utilities Stock: &#8216;I Think You&#8217;ve Got A Good One&#8217;</a>
Leading and Lagging Sectors Information technology shares surged by 1.5% on Monday.
In trading on Monday, real estate shares fell by 0.7%.
Top Headline
Shares of McDonald's Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) gained around 5% on Monday following the release of fourth-quarter results.
The company reported a fourth-quarter sales decline of 0.3% year-on-year to $6.388 billion, missing the analyst consensus estimate of $6.442 billion. Adjusted EPS of $2.83 was in line with the analyst consensus estimate.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Brand Engagement Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) shares shot up 107% to $0.8625.</li>
<li>Shares of Biodexa Pharmaceuticals Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>)got a boost, surging 70% to $6.93 after the company announced it received FDA fast-track designation for eRapa.</li>
<li>Global Star Acquisition, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLST#NASDAQ">GLST</a>) shares were also up, gaining 58% to $17.32.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Pliant Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) shares dropped 60% to $3.1075. On Friday, Pliant Therapeutics announced it has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and stiffening of the lung tissue.</li>
<li>Shares of FBS Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBGL#NASDAQ">FBGL</a>) were down 33% to $1.2050.</li>
<li>Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) was down, falling 31% to $37.46 after Needham cut its price target on the stock from $74 to $54.</li>
</ul>
Commodities In commodity news, oil traded up 1.4% to $71.99 while gold traded up 1.5% at $2,931.10.
Silver traded up 0.6% to $32.635 on Monday, while copper rose 2% to $4.6820.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.5%, Germany's DAX 40 rose 0.6% and France's CAC 40 rose 0.3%. Spain's IBEX 35 Index rose 0.1%, while London's FTSE 100 rose 0.8%.
Asia Pacific Markets
Asian markets closed mostly higher on Monday, with Japan's Nikkei 225 gaining 0.04%, China's Shanghai Composite Index climbing 0.56%, Hong Kong's Hang Seng Index gaining 1.84% and India's BSE Sensex falling 0.70%.
Economics
Data on US consumer inflation expectations will be released today
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43593480/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-with-over-6-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields</a></li>
</ul>

Eurozone

Commodities

Intraday Update

BDRX

BNAI

FBGL

GLST

PLRX

SMTC

Dow Gains 100 Points; McDonald's Shares Rise After Q4 Results

Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) is set to report <a href="https://www.benzinga.com/quote/VRTX/earnings">fourth quarter earnings</a> after the market closes Monday. Biotech investors are bracing for impact.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="631" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10085744/Screenshot-2025-02-10-at-7.27.22-PM.png" alt="" class="wp-image-774596" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10085744/Screenshot-2025-02-10-at-7.27.22-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10085744/Screenshot-2025-02-10-at-7.27.22-PM-300x231.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021025&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The stock has climbed 15.66% year-to-date, recovering from last year's volatility. With selling pressure creeping in, the question is whether this rally has legs, or if it&#8217;s time for a reset.
<h2 class="wp-block-heading">Wall Street's Expectations: Solid Numbers Or A Reality Check?</h2>
Wall Street expects Vertex to post EPS of $4.03 on revenue of $2.78 billion, per <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021025&amp;t=be2bearmibe3na1">Benzinga Pro</a> data. 
But beyond the numbers, the real focus is on the company's upcoming drug launches and how they could fuel future growth.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43526731/unitedhealth-vertex-pharmaceuticals-axon-enterprise-and-a-major-energy-stock-cnbcs-final-trades">UnitedHealth, Vertex Pharmaceuticals, Axon Enterprise And A Major Energy Stock: CNBC&#8217;s &#8216;Final Trades&#8217;</a>
<h2 class="wp-block-heading">Pipeline Watch: Can Alyftrek And Suzetrigine Deliver?</h2>
JPMorgan analyst Jessica Fye sees 2025 as a make-or-break year for Vertex.
The company is rolling out Alyftrek, its latest cystic fibrosis (CF) treatment and preparing for a potential suzetrigine launch in acute pain. Investors will be watching management's commentary on these new products closely, especially after suzetrigine's mixed Phase II results in LSR (large sensory neuropathy).
Fye expects a solid launch for Alyftrek, modeling $376 million in 2025 revenue though but suzetrigine's adoption remains uncertain, with pricing a key factor.
<h2 class="wp-block-heading">VRTX Stock Technicals: Bullish, But With Risks</h2>
Technicals are giving mixed signals. VRTX stock is trading at $469.32, above its eight-day, 20-day, 50-day and 200-day moving averages, flashing buy signals across the board.
The MACD (moving average convergence/divergence) indicator is bullish. RSI (relative strength index) at 62.06 suggests there&#8217;s still room to run.
But selling pressure is creeping in, hinting at potential turbulence ahead.
<h2 class="wp-block-heading">Can Vertex Stock Keep Its Momentum?</h2>
Vertex needs to deliver more than just a solid quarter though investors want confidence in its 2025 pipeline. Any slip-up in guidance could shake the stock's recent momentum. Stay tuned.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43589292/top-wall-street-forecasters-revamp-vertex-pharmaceuticals-price-expectations-ahead-of-q4-earnings">Top Wall Street Forecasters Revamp Vertex Pharmaceuticals Price Expectations Ahead Of Q4 Earnings</a></li>
</ul>
Photo: Shutterstock

Technicals

Previews

VRTX

Vertex Q4 Earnings On Deck: Will This Biotech Heavyweight Keep Its Edge?

JMP Securities analyst Matthew Carletti reiterates Skyward Specialty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKWD#NASDAQ">SKWD</a>) with a Market Outperform and maintains $60 price target.

SKWD

JMP Securities Reiterates Market Outperform on Skyward Specialty, Maintains $60 Price Target

U.S. IPO Weekly Recap: Small Issuers Keep The October IPO Market Moving

Self-driving startup Pony.ai of China filed for an IPO in the U.S. this week. Meanwhile, four companies -- Springview Holdings, Oriental Rise Holdings, PTL Limited, and Samfine Creation Holdings Group -- saw their stocks open for trading.

Self-Driving Startup Pony.ai Files For U.S. IPO

09:52 EST PTL (PTLE) Ltd trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try ...

PTL Ltd trading resumes

09:47 EST PTL (PTLE) Ltd trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving brea...

PTL Ltd trading halted, volatility trading pause

09:36 EST PTL (PTLE) Ltd trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try ...

09:31 EST PTL (PTLE) Ltd trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving brea...

16:00 EST PTL (PTLE) Ltd trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try ...

15:35 EST PTL (PTLE) Ltd trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving brea...

BIOA

CGGJ

CURX

GRDN

INGM

LGCY

ORIS

PONY

SFHG

SPHL

IPOs

Press Releases

PTL Limited Announces Pricing of $5 million Initial Public Offering and Listing on Nasdaq

PTL Limited Announces Closing of Initial Public Offering

PTL Limited Announced Full Exercise of Underwriter's Over-Allotment Option

CBL International Limited - Ordinary Shares

CBL International

Brooge Energy

Clean Energy Technologies, Inc. - Common Stock

Clean Energy Technologies

Crown LNG Holdings Limited - Ordinary Shares

Crown LNG Holdings

Dynagas LNG Partners

EzFill Holdings

Imperial Ptrl

Martin Midstream Partners L.P. - Common Units Representing Limited Partnership Interests

Comments

PTL

Noticias

Últimas noticias sobre PTL (NASDAQ:PTLE) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL